TY - JOUR
T1 - Study Protocol for the DETECTIVE Study
T2 - An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer
AU - Lam, Thomas B.L.
AU - MacLennan, Steven
AU - Plass, Karin
AU - Willemse, Peter Paul M.
AU - Mason, Malcolm D.
AU - Cornford, Philip
AU - Donaldson, James
AU - Davis, Niall F.
AU - Dell'Oglio, Paolo
AU - Fankhauser, Christian
AU - Grivas, Nikos
AU - Ingels, Alexandre
AU - Lardas, Michael
AU - Liew, Matthew
AU - Pang, Karl H.
AU - Paterson, Catherine
AU - Omar, Muhammad I.
AU - Zattoni, Fabio
AU - Buddingh, Karel T.
AU - Van den Broeck, Thomas
AU - Cumberbatch, Marcus G.
AU - Fossati, Nicola
AU - Gross, Tobias
AU - Moris, Lisa
AU - Schoots, Ivo G.
AU - van den Bergh, Roderick C.N.
AU - Briers, Erik
AU - Fanti, Stefano
AU - De Santis, Maria
AU - Gillessen, Silke
AU - Grummet, Jeremy P.
AU - Henry, Ann M.
AU - van der Poel, Henk G.
AU - van der Kwast, Theodorus H.
AU - Rouvière, Olivier
AU - Tilki, Derya
AU - Wiegel, Thomas
AU - N'Dow, James
AU - Van Poppel, Hendrik
AU - Mottet, Nicolas
PY - 2019/4
Y1 - 2019/4
N2 - Deferred active treatment (DAT) strategies for men with localised prostate cancer have emerged as a viable alternative to radical intervention as we aim to avoid the consequences of overtreatment. Nevertheless, such strategies remain controversial, with significant uncertainty and heterogeneity in all domains, including criteria for patient selection, the nature and timing of interventions during follow-up, criteria and thresholds for reclassification, and which outcome measures should be prioritised [1–3]. These are important barriers to the conduct and uptake of DAT by clinicians and patients as they prohibit comparison of the clinical effectiveness of different protocols. In order to address these issues in a comprehensive, robust, and systematic manner, the European Association of Urology (EAU) Prostate Cancer Guidelines Panel, in partnership with other leading guideline authorities and organisations (listed in Appendix A), has commissioned a project to develop consensus statements for all domains relating to DAT to standardise clinical practice and research.
AB - Deferred active treatment (DAT) strategies for men with localised prostate cancer have emerged as a viable alternative to radical intervention as we aim to avoid the consequences of overtreatment. Nevertheless, such strategies remain controversial, with significant uncertainty and heterogeneity in all domains, including criteria for patient selection, the nature and timing of interventions during follow-up, criteria and thresholds for reclassification, and which outcome measures should be prioritised [1–3]. These are important barriers to the conduct and uptake of DAT by clinicians and patients as they prohibit comparison of the clinical effectiveness of different protocols. In order to address these issues in a comprehensive, robust, and systematic manner, the European Association of Urology (EAU) Prostate Cancer Guidelines Panel, in partnership with other leading guideline authorities and organisations (listed in Appendix A), has commissioned a project to develop consensus statements for all domains relating to DAT to standardise clinical practice and research.
KW - Prostate Cancer
KW - Treatment
KW - Curative Intent
UR - http://www.scopus.com/inward/record.url?scp=85062005138&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2018.11.009
DO - 10.1016/j.eururo.2018.11.009
M3 - Letter
C2 - 30473433
AN - SCOPUS:85062005138
SN - 0302-2838
VL - 75
SP - 699
EP - 702
JO - European Urology
JF - European Urology
IS - 4
ER -
